Mar 28, 2020
Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol
Nov 15, 2019
Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors
Oct 24, 2019
Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Mar 15, 2019
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
Feb 25, 2019
Jury Upholds Amgen's Patents On Repatha® (evolocumab)
Nov 12, 2018
Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
Oct 26, 2018
Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease
Oct 24, 2018
Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price
Aug 29, 2018
Lower Cholesterol Treatment Breakthrough
Mar 23, 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes
Mar 09, 2018
New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events
Feb 26, 2018
Amgen To Present New Data From Repatha® (evolocumab) Clinical Trials At ACC.18
Feb 22, 2018
Abarca, Amgen Enter Outcomes-Based Agreement For Repatha® (evolocumab)
Dec 01, 2017
FDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke
Nov 06, 2017
Amgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017
Aug 23, 2017
New Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology
Jul 27, 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events